Exchange Traded Concepts LLC Has $1.29 Million Stock Holdings in United Therapeutics Corporation $UTHR

Exchange Traded Concepts LLC reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,487 shares of the biotechnology company’s stock after selling 156 shares during the period. Exchange Traded Concepts LLC’s holdings in United Therapeutics were worth $1,289,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vaughan Nelson Investment Management L.P. bought a new stake in United Therapeutics in the first quarter worth about $101,354,000. Nuveen LLC purchased a new position in United Therapeutics during the first quarter valued at approximately $83,533,000. Amundi grew its stake in United Therapeutics by 198.8% during the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock valued at $107,635,000 after acquiring an additional 232,988 shares in the last quarter. GAMMA Investing LLC grew its stake in United Therapeutics by 29,415.2% during the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock valued at $68,422,000 after acquiring an additional 221,202 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in United Therapeutics by 1,657.8% during the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock valued at $55,217,000 after acquiring an additional 169,010 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on UTHR shares. Bank of America boosted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a research note on Wednesday, September 3rd. Oppenheimer boosted their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Finally, JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $438.85.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $414.73 on Tuesday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The firm has a 50-day moving average of $331.90 and a 200 day moving average of $311.38. The stock has a market cap of $18.71 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 6.37 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the business posted $5.85 EPS. United Therapeutics’s revenue for the quarter was up 11.7% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 176,435 shares of company stock valued at $65,503,807. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.